Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Medical Genetics

Building Your Care Team for MPI-CDG

At a Glance

Children with MPI-CDG need coordinated, long-term care rather than one doctor alone. A metabolic geneticist can lead a team that includes liver, gastrointestinal, blood, and primary care specialists, with shared records and an emergency plan for illness or low blood sugar.

Because MPI-CDG (CDG-Ib) is an ultra-rare condition that affects multiple systems, your child’s care cannot be managed by a single doctor. Instead, you will need a multidisciplinary care team—a group of specialists who work together to monitor your child’s health from different angles [1][2]. Organizing this team early is the best way to ensure your child receives the comprehensive monitoring they need for long-term safety [3]. Not every patient needs every specialist at all times; this is an individualized coordination model where additional experts are involved according to documented clinical problems.

Your Core Specialist Roster

A successful care team for MPI-CDG typically includes the following specialists:

  • Metabolic Geneticist (The Team Lead): This specialist is often the “captain” of the team. They confirm the genetic diagnosis, oversee lifelong D-mannose therapy, and interpret complex lab tests like transferrin patterns [1][4]. They are also responsible for creating your child’s emergency protocol for illnesses or low blood sugar [5].
  • Pediatric Hepatologist (Liver Specialist): Because liver disease can progress “silently” in MPI-CDG, a hepatologist is essential [6][7]. They monitor for liver scarring (fibrosis) and increased pressure in the liver’s veins (portal hypertension) using specialized imaging rather than just standard blood tests [3][6].
  • Gastroenterologist (GI Specialist): This doctor focuses on managing protein-losing enteropathy (PLE), chronic diarrhea, and vomiting [1][3]. They work closely with a registered dietitian to ensure your child is absorbing enough nutrients to grow and thrive [2].
  • Hematologist (Blood Specialist): A hematologist monitors your child’s risk for blood clots (thrombosis) [8]. They track levels of natural “blood thinners” like Antithrombin and Protein C/S, which are often low in MPI-CDG [8][9].
  • Endocrinologist: In some cases, an endocrinologist may help manage hyperinsulinemic hypoglycemia (low blood sugar caused by too much insulin), though this is sometimes managed by the metabolic geneticist [10][1].
  • Primary Care Clinician: A pediatrician handles routine health, vaccinations, and common illnesses, working closely with the metabolic lead.
  • Genetic Counselor: They help discuss the inheritance pattern, testing for family members, and future reproductive planning.

Preparing for the First Appointment

When you meet a new specialist, you are often the most knowledgeable person in the room regarding your child’s specific history. To make the most of these visits, bring a “specialist toolkit” containing the following records [11][1]:

  1. The Genetic Report: The complete lab results showing the specific MPI variants (mutations) your child has [4].
  2. Screening Results: Copies of any Transferrin Isoelectric Focusing (TIEF) or other glycosylation patterns [7][5].
  3. Baseline Imaging: Reports and images from any ultrasounds or MRIs of the liver, spleen, or kidneys [6].
  4. Blood Sugar Logs: Records of any low blood sugar episodes, including what the sugar level was and how it was treated [5].
  5. Coagulation Panels: Lab results for Antithrombin, Protein C, Protein S, and Factor XI [8][3].
  6. Medication Timeline: A clear record of when your child started D-mannose, the current dose, and how their symptoms have changed since starting [3].

The Importance of Communication

In an ultra-rare disease, the biggest risk to a patient is often “siloed” care—where the liver doctor doesn’t know what the blood doctor is doing. Ask your specialists how they plan to communicate with each other [1]. Ideally, all specialists should have access to a single shared care plan and a copy of your child’s emergency metabolic letter [1][3].

As your child grows, this team will likely expand to include other specialists, such as a nephrologist (kidney doctor) or an immunologist, as needed [3][12]. Keeping a centralized “medical home” with a strong metabolic lead ensures that as your child transitions into adulthood, their monitoring remains consistent, they can learn to take ownership of their own medications and protocols, and their history is never lost [2][13].

Common questions in this guide

Which doctors are usually part of an MPI-CDG care team?
The core team usually includes a metabolic geneticist, pediatric hepatologist, gastroenterologist, hematologist, and primary care clinician. An endocrinologist, genetic counselor, registered dietitian, nephrologist, or immunologist may join when your child’s needs call for them.
What does the metabolic geneticist do for a child with MPI-CDG?
The metabolic geneticist often coordinates the overall team, confirms the genetic diagnosis, oversees D-mannose therapy, and interprets tests such as transferrin patterns. They also help create the emergency plan for illness or low blood sugar.
What should I bring to my child’s MPI-CDG specialist visits?
Bring the complete genetic report, glycosylation or transferrin testing, liver and other imaging reports, blood sugar logs, coagulation results, and a medication timeline. Include the D-mannose dose and any changes in symptoms since treatment began.
Can MPI-CDG liver or clotting problems be missed by routine blood tests?
They can be, because liver disease may progress silently and standard blood tests may not show liver fibrosis or portal hypertension. The care team may use specialized liver imaging and coagulation tests, including antithrombin and Protein C and S levels, to monitor these risks.
How should MPI-CDG specialists communicate with one another?
The team should use one shared care plan and keep an up-to-date emergency metabolic letter available. Families can also ask who will share liver, gastrointestinal, blood, and medication updates and which number to call after hours.
What should we do if our child becomes ill or misses a D-mannose dose?
Follow your child’s written emergency metabolic protocol and use the agreed after-hours contact for gastrointestinal illness, low blood sugar, or a missed D-mannose dose. Because instructions are individualized, ask the metabolic team in advance what steps to take rather than guessing.
How can I keep my child’s MPI-CDG care organized as they grow?
Keep a physical binder or secure digital folder with genetic reports, imaging, laboratory results, medication details, and care plans. Track appointments and recommendations in one place, share the emergency protocol with school or caregivers, and ask the team to plan for a gradual transition to adult care.

Get notified when new evidence is published on MPI-CDG.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Consensus guideline for the diagnosis and management of mannose phosphate isomerase-congenital disorder of glycosylation.

    Čechová A, Altassan R, Borgel D, et al.

    Journal of inherited metabolic disease 2020; (43(4)):671-693 doi:10.1002/jimd.12241.

    PMID: 32266963
  2. 2

    Management of pregnancy and outcomes in a woman with mannose-6-phosphate isomerase deficiency (MPI-CDG).

    Loh JHM, Khin MO, Bassett J, et al.

    Molecular genetics and metabolism reports 2026; (48()):101329 doi:10.1016/j.ymgmr.2026.101329.

    PMID: 42376639
  3. 3

    Long term outcome of MPI-CDG patients on D-mannose therapy.

    Girard M, Douillard C, Debray D, et al.

    Journal of inherited metabolic disease 2020; (43(6)):1360-1369 doi:10.1002/jimd.12289.

    PMID: 33098580
  4. 4

    Mannose phosphate isomerase-congenital disorder of glycosylation leads to asymptomatic hypoglycemia.

    Luo C, Peng D, Li Y, et al.

    Molecular genetics and metabolism reports 2024; (41()):101162 doi:10.1016/j.ymgmr.2024.101162.

    PMID: 40206417
  5. 5

    Protein losing enteropathy due to congenital disorder of glycosylation: A case report.

    Odenthal J, Lin HC, Trieschmann K

    SAGE open medical case reports 2025; (13()):2050313X251397063 doi:10.1177/2050313X251397063.

    PMID: 41282383
  6. 6

    [Clinical characteristics and D-mannose treatment outcomes in 5 children with mannose phosphate isomerase-congenital disorders of glycosylation].

    Zhang Y, Li LT, Wang NL, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2025; (63(10)):1136-1141 doi:10.3760/cma.j.cn112140-20250513-00403.

    PMID: 40962549
  7. 7

    MPI-CDG from a hepatic perspective: Report of two Egyptian cases and review of literature.

    Abdel Ghaffar TY, Ng BG, Elsayed SM, et al.

    JIMD reports 2020; (56(1)):20-26 doi:10.1002/jmd2.12159.

    PMID: 33204592
  8. 8

    Mannose phosphate isomerase deficiency-congenital disorder of glycosylation (MPI-CDG) with cerebral venous sinus thrombosis as first and only presenting symptom: A rare but treatable cause of thrombophilia.

    Mühlhausen C, Henneke L, Schlotawa L, et al.

    JIMD reports 2020; (55(1)):38-43 doi:10.1002/jmd2.12149.

    PMID: 32905087
  9. 9

    Oral D-mannose therapy during pregnancy in a woman with MPI-CDG: A case report and management review.

    Martzolff L, Raynor A, Lebredonchel E, et al.

    Molecular genetics and metabolism 2025; (146(4)):109269 doi:10.1016/j.ymgme.2025.109269.

    PMID: 41172867
  10. 10

    A Case of Congenital Disorder of Glycosylation Type 1b Presenting as Hyperinsulinemic Hypoglycemia and Failure to Thrive.

    Rani S, Sahai I, Misra M

    JCEM case reports 2023; (1(5)):luad109 doi:10.1210/jcemcr/luad109.

    PMID: 37908211
  11. 11

    Mannose phosphate isomerase gene mutation leads to a congenital disorder of glycosylation: A rare case report and literature review.

    Lu S, Liang S, Wu Y, et al.

    Frontiers in pediatrics 2023; (11()):1150367 doi:10.3389/fped.2023.1150367.

    PMID: 37124179
  12. 12

    Mannose treatment improves immune deficiency in mannose phosphate isomerase-congenital disorder of glycosylation: case report and review of literature.

    De Graef D, Mousa J, Waberski MB, Morava E

    Therapeutic advances in rare disease 2022; (3()):26330040221091283 doi:10.1177/26330040221091283.

    PMID: 37180423
  13. 13

    Clinical outcomes in an adult patient with mannose phosphate isomerase-congenital disorder of glycosylation who discontinued mannose therapy.

    Noman K, Hendriksz CJ, Radcliffe G, et al.

    Molecular genetics and metabolism reports 2020; (25()):100646 doi:10.1016/j.ymgmr.2020.100646.

    PMID: 32963965

This page is for informational purposes only and does not constitute medical advice about your child’s MPI-CDG care. Their metabolic team should tailor monitoring, medicines, and emergency instructions to their needs.